Deletions found in the TKI-resistant CML samples
ID . | Chromosome . | Starting position . | Ending position . | Length, Mb . | Candidate genes . | Treatment . | Disease status . |
---|---|---|---|---|---|---|---|
2 | 1p36 | 8206962 | 9061724 | 0.85 | RERE, ENO-1 | Imatinib, DA, nilotinib, dasatinib | Myeloid blast crisis |
40-R* | 2p14 | 67344057 | 67586748 | 0.24 | ETAA1 | Imatinib | Myeloid blast crisis |
40-R* | 2p14 | 67726052 | 67862441 | 0.13 | No gene | Imatinib | Myeloid blast crisis |
40-R* | 3q26 | 182773194 | 183414855 | 0.64 | SOX2 | Imatinib | Myeloid blast crisis |
45-R* | 3q13 | 107395968 | 113108377 | 5.71 | Imatinib | Unknown | |
34 | 6p22 | 21716958 | 22106421 | 0.39 | FLJ22536 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
45-R* | 6p12 | 47456409 | 54815576 | 7.35 | Imatinib | Unknown | |
40-R* | 8p | 180568 | 28696690 | 28.51 | INTS9 | Imatinib | Myeloid blast crisis |
45-R | 8q12 | 56513192 | 56568360 | 0.05 | SBF1B1, homo del | Imatinib | Unknown |
34 | 9p | 30910 | 130700428 | 130.70 | Del der Chromosome 9 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
12 | 9q34 | 128779763 | 130659964 | 1.88 | ABL1-PHYHD1 | Imatinib | Unknown |
32-R | 9q34 | 128779763 | 130643119 | 1.86 | ABL1-PHYHD1 | Imatinib | CML in hematologic remission |
41-R | 9q34 | 128779763 | 130760738 | 1.98 | ABL1-PHYHD1 | Imatinib | Unknown |
44-R | 9q34 | 129888844 | 130775671 | 0.88 | ABL1-GPR107 | Imatinib | CML in hematologic remission |
43-R | 9q34 | 130889873 | 131275779 | 0.38 | LAMC3, AIF1L, NUP214 and more | Imatinib | Unknown |
40-R8 | 9q33 | 117671985 | 119985986 | 2.31 | DBC1 | Imatinib | Myeloid blast crisis |
33-R | 10q21 | 67879503 | 67935343 | 0.06 | CTNNA3 | DA, imatinib | Myeloid blast crisis |
45-R* | 11q | 89538451 | 92629460 | 3.09 | Imatinib | Unknown | |
34 | 12p12 | 14971302 | 17224159 | 2.25 | ERP27, RERG, PTPRO + other genes | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
34 | 12p12 | 25334604 | 25429100 | 0.09 | No gene | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
40-R* | 12p11 | 28549306 | 28659885 | 0.11 | CCDC91 | Imatinib | Myeloid blast crisis |
35 | 14q31 | 85977359 | 86198515 | 0.22 | No gene | HU + IFN, imatinib | CML |
34 | 15q15 | 38796960 | 41889601 | 3.09 | RAD51-MFAP1 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
40-R* | 16q | 45065445 | 88690776 | 43.62 | Imatinib | Myeloid blast crisis | |
27 | 17p | 18901 | 22029237 | 22.01 | p53 | Imatinib | Unknown |
40-R* | 17p | 18901 | 21346948 | 21.32 | p53 | Imatinib | Myeloid blast crisis |
46-R* | 17p | 18901 | 18857962 | 18.83 | p53 | Unknown | CML |
34 | 17q12 | 32663038 | 33785091 | 1.12 | ACACA-SOCS7 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
2 | 22q11 | 20724157 | 20832986 | 0.11 | IGLC1 | Imatinib, DA, nilotinib, dasatinib | Myeloid blast crisis |
22-R* | 22q11 | 20724157 | 20832986 | 0.11 | IGLC1 | Imatinib | Lymphoid blast crisis |
34 | 22q11 | 20685204 | 20859240 | 0.17 | IGLC1 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
12 | 22q11 | 21970272 | 23413582 | 1.44 | BCR-GGT1 | Imatinib | Unknown |
41-R | 22q11 | 21947838 | 23157101 | 1.20 | BCR, ADORA2A | Imatinib | Unknown |
44-R | 22q11 | 21939318 | 27992558 | 6.05 | BCR, CHEK2 | Imatinib | CML in hematologic remission |
32-R | 22q11 | 22353181 | 23209777 | 0.79 | VPREB3 | Imatinib | CML in hematologic remission |
43-R | 22q11 | 22860184 | 23556124 | 0.69 | CABIN1-PIWIL3 | Imatinib | Unknown |
ID . | Chromosome . | Starting position . | Ending position . | Length, Mb . | Candidate genes . | Treatment . | Disease status . |
---|---|---|---|---|---|---|---|
2 | 1p36 | 8206962 | 9061724 | 0.85 | RERE, ENO-1 | Imatinib, DA, nilotinib, dasatinib | Myeloid blast crisis |
40-R* | 2p14 | 67344057 | 67586748 | 0.24 | ETAA1 | Imatinib | Myeloid blast crisis |
40-R* | 2p14 | 67726052 | 67862441 | 0.13 | No gene | Imatinib | Myeloid blast crisis |
40-R* | 3q26 | 182773194 | 183414855 | 0.64 | SOX2 | Imatinib | Myeloid blast crisis |
45-R* | 3q13 | 107395968 | 113108377 | 5.71 | Imatinib | Unknown | |
34 | 6p22 | 21716958 | 22106421 | 0.39 | FLJ22536 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
45-R* | 6p12 | 47456409 | 54815576 | 7.35 | Imatinib | Unknown | |
40-R* | 8p | 180568 | 28696690 | 28.51 | INTS9 | Imatinib | Myeloid blast crisis |
45-R | 8q12 | 56513192 | 56568360 | 0.05 | SBF1B1, homo del | Imatinib | Unknown |
34 | 9p | 30910 | 130700428 | 130.70 | Del der Chromosome 9 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
12 | 9q34 | 128779763 | 130659964 | 1.88 | ABL1-PHYHD1 | Imatinib | Unknown |
32-R | 9q34 | 128779763 | 130643119 | 1.86 | ABL1-PHYHD1 | Imatinib | CML in hematologic remission |
41-R | 9q34 | 128779763 | 130760738 | 1.98 | ABL1-PHYHD1 | Imatinib | Unknown |
44-R | 9q34 | 129888844 | 130775671 | 0.88 | ABL1-GPR107 | Imatinib | CML in hematologic remission |
43-R | 9q34 | 130889873 | 131275779 | 0.38 | LAMC3, AIF1L, NUP214 and more | Imatinib | Unknown |
40-R8 | 9q33 | 117671985 | 119985986 | 2.31 | DBC1 | Imatinib | Myeloid blast crisis |
33-R | 10q21 | 67879503 | 67935343 | 0.06 | CTNNA3 | DA, imatinib | Myeloid blast crisis |
45-R* | 11q | 89538451 | 92629460 | 3.09 | Imatinib | Unknown | |
34 | 12p12 | 14971302 | 17224159 | 2.25 | ERP27, RERG, PTPRO + other genes | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
34 | 12p12 | 25334604 | 25429100 | 0.09 | No gene | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
40-R* | 12p11 | 28549306 | 28659885 | 0.11 | CCDC91 | Imatinib | Myeloid blast crisis |
35 | 14q31 | 85977359 | 86198515 | 0.22 | No gene | HU + IFN, imatinib | CML |
34 | 15q15 | 38796960 | 41889601 | 3.09 | RAD51-MFAP1 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
40-R* | 16q | 45065445 | 88690776 | 43.62 | Imatinib | Myeloid blast crisis | |
27 | 17p | 18901 | 22029237 | 22.01 | p53 | Imatinib | Unknown |
40-R* | 17p | 18901 | 21346948 | 21.32 | p53 | Imatinib | Myeloid blast crisis |
46-R* | 17p | 18901 | 18857962 | 18.83 | p53 | Unknown | CML |
34 | 17q12 | 32663038 | 33785091 | 1.12 | ACACA-SOCS7 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
2 | 22q11 | 20724157 | 20832986 | 0.11 | IGLC1 | Imatinib, DA, nilotinib, dasatinib | Myeloid blast crisis |
22-R* | 22q11 | 20724157 | 20832986 | 0.11 | IGLC1 | Imatinib | Lymphoid blast crisis |
34 | 22q11 | 20685204 | 20859240 | 0.17 | IGLC1 | HU, ICT, imatinib, dasatinib | Lymphoid blast crisis |
12 | 22q11 | 21970272 | 23413582 | 1.44 | BCR-GGT1 | Imatinib | Unknown |
41-R | 22q11 | 21947838 | 23157101 | 1.20 | BCR, ADORA2A | Imatinib | Unknown |
44-R | 22q11 | 21939318 | 27992558 | 6.05 | BCR, CHEK2 | Imatinib | CML in hematologic remission |
32-R | 22q11 | 22353181 | 23209777 | 0.79 | VPREB3 | Imatinib | CML in hematologic remission |
43-R | 22q11 | 22860184 | 23556124 | 0.69 | CABIN1-PIWIL3 | Imatinib | Unknown |
Copy number alterations (CNAs) in TKI-resistant samples without a matched diagnostic sample are shown with plain numbers in the column “ID.” CNAs in TKI-resistant samples with a matched diagnostic sample with the CNAs being present in both the diagnostic sample and the resistant sample are shown with numbers + “R” in the column “ID.” CNAs which were newly acquired in matched resistant samples compared to the diagnostic samples are shown with numbers + “R*” in the column “ID.”
ID indicates patient ID; Starting position, start position of genomic lesion; Ending position, end position of genomic lesion; HU, hydroxyurea; DA, daunorubicin plus cytarabine; ICT, induction chemotherapy; and IFN, interferon-α.